Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLAS-PEDS: Fitusiran prophylaxis in pediatric hemophilia A or B
2019-000679-18Phase 2Recruiting
- Sponsor
- Sanofi
- Start
- Apr 2019
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fitusiran in hemophilia A and hemophilia B (HB), sponsored by Sanofi. Primary endpoint: Plasma antithrombin activity reduction at Day 85. Started Apr 2019; status: recruiting.
02
Drugs
fitusiran
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on 2019-000679-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000679-18.